NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.arbutusbio.comThe patent for ONPATTRO (US8642076), related to nucleic acid-based therapies, is set to expire on October 3, 2027. This patent, jointly assigned to Arbutus Biopharma Corp and Alnylam Pharmaceuticals Inc, protects compositions and methods for administering these therapies using techniques such as liposomes and lipoplexes. The expiration may impact market dynamics for the product and its competitors, potentially allowing for generic formulations to enter the market, which could affect pricing and revenue for the involved companies.
patent expirationThe U.S. patent US8822668, associated with ONPATTRO, is set to expire on April 15, 2029. ONPATTRO is a therapy developed as stable nucleic acid-lipid particles (SNALP), designed for the delivery of RNAi therapies. The expiration of this patent could open the market to generic alternatives, impacting Arbutus Biopharma Corp and Alnylam Pharmaceuticals Inc., the companies linked to the patent. Such a shift may influence their competitive position and revenue streams as patent protections diminish.
Patent ExpirationPatent US8802644 related to ONPATTRO is set to expire on October 21, 2030. This patent, held by Arbutus Biopharma Corp and Alnylam Pharmaceuticals Inc, covers an innovative cationic lipid formulation, which is crucial for the product's mechanism and effectiveness. The expiration may impact the competitive landscape for ONPATTRO, potentially allowing market entry for generic alternatives and influencing pricing strategies for the drug.
Patent ExpiryThe patent US8158601 related to ONPATTRO, a lipid nanoparticle drug designed to deliver RNA interference therapies, is set to expire on November 10, 2030. This expiration may permit generic competition in the market, affecting pricing and market share for Arbutus Biopharma Corp and Alnylam Pharmaceuticals Inc. The patent covers a unique cationic lipid formulation that is integral to ONPATTRO's delivery method, crucial for its therapeutic applications in treating specific genetic diseases.
Patent Expiration